Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current HIV/AIDS Reports
Published in: Current HIV/AIDS Reports 4/2010

01-11-2010

Implementation Science of Pre-exposure Prophylaxis: Preparing for Public Use

Authors: Kristen Underhill, Don Operario, Matthew J. Mimiaga, Margie R. Skeer, Kenneth H. Mayer

Published in: Current HIV/AIDS Reports | Issue 4/2010

Login to get access

Abstract

As efficacy trials of antiretroviral pre-exposure prophylaxis (PrEP) continue, a growing literature has begun anticipating the potential challenges of implementing PrEP for HIV prevention. These efforts coincide with a shift toward combination interventions for preventing HIV, which integrate biomedical, behavioral, and structural components. The optimal implementation of PrEP would exemplify this combination model, incorporating not only PrEP drugs, but also HIV testing, safety screening, behavioral interventions addressing adherence and risk behavior, and long-term monitoring. Efforts to plan for PrEP implementation therefore present an opportunity to advance the science of implementation and delivery in HIV prevention, in order to better address the challenges of scaling up combination approaches. We review the published and unpublished literature on PrEP implementation, organizing themes into five categories: scientific groundwork, regulatory and policy groundwork, stakeholder and infrastructure groundwork, delivery, and long-term monitoring. The lessons from PrEP planning can benefit the scale-up of future combination interventions.
Literature
1.
UNAIDS: Global Facts & Figures. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS; 2009.
2.
Lagakos SW, Gable AR: Challenges to HIV prevention—seeking effective measures in the absence of a vaccine. N Engl J Med 2008, 358:1543–1545.CrossRefPubMed
3.
Padian NS, Buvé A, Balkus J, et al.: Biomedical interventions to prevent HIV infection: evidence, challenges, and way forward. Lancet 2008, 372:585–599.CrossRefPubMed
4.
Cohen MS, Gay C, Kashuba ADM, et al.: Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann Intern Med 2007, 146:591–601.PubMed
5.
• Paxton LA, Hope T, Jaffe HW: Pre-exposure prophylaxis for HIV infection: what if it works? Lancet 2007, 370:89–93. This article outlines possible implications of PrEP trial results, including implementation challenges.CrossRefPubMed
6.
7.
Abbas UL, Anderson RM, Mellors JW: Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settings. PLoS ONE 2007, 2:e875.CrossRefPubMed
8.
• Desai K, Sansom SL, Ackers ML, et al.: Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness. AIDS 2008, 22:1829–1839. This article constructs a mathematical model of PrEP’s potential public health impact in the US, focusing on urban MSM, and concludes that PrEP may be cost-effective within a range of efficacy.CrossRefPubMed
9.
Paltiel AD, Freedberg KA, Scott CA, et al.: HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis 2009, 48:806–815.CrossRefPubMed
10.
• Vissers DCJ, Voeten HACM, Nagelkerke NJD, et al.: The impact of pre-exposure prophylaxis (PrEP) on HIV epidemics in Africa and India: a simulation study. PLoS ONE 2008, 3:e2077. This article models the impact of PrEP in several settings of Africa and India, concluding that PrEP could have a substantial impact, but that this impact could be diminished by changes in risk behavior.CrossRefPubMed
11.
Abdool Karim SS: Antiretroviral chemoprophylaxis for the prevention of HIV infection: future implementation challenges. HIV Ther 2009, 3:3–6.CrossRef
12.
Coates TJ, Szekeres G: Think tank: Policy and practice implications of HIV pre-exposure prophlaxis (PrEP) in the United States—Meeting proceedings. Los Angeles, CA: UCLA Program in Global Health; 2006.
13.
Liu AY, Grant RM, Buchbinder SP: Preexposure prophylaxis for HIV: unproven promise and potential pitfalls. JAMA 2006, 296:863–865.CrossRefPubMed
14.
Szekeres G, Coates TJ: Policy and practice implications of HIV pre-exposure prophylaxis (PrEP) in the United States. Los Angeles, CA: UCLA Program in Global Health, AIDS Policy Development Center; 2006.
15.
Szekeres G, Coates TJ, Frost S, et al.: Anticipating the efficacy of HIV pre-exposure prophylaxis (PrEP) and the needs of at-risk Californians. Oakland, CA: AIDS Partnership California; 2004.
16.
Underhill K, Operario D, Skeer M, et al.: Packaging PrEP to prevent HIV: An integrated framework to plan for pre-exposure prophylaxis in clinical practice. J Acquir Immune Defic Syndr 2010, In press.
17.
Rotheram-Borus MJ, Swendeman D, Chovnick G: The past, present, and future of HIV prevention: integrating behavioral, biomedical, and structural intervention strategies for the next generation of HIV prevention. Annu Rev Clin Psychol 2009, 143–167.
18.
Cohen J: Prevention cocktails: combining tools to stop HIV’s spread. Science 2005, 309:1002–1005.CrossRefPubMed
19.
20.
AIDS Vaccine Advocacy Coalition: Part of the solution: setting expectations for WHO and UNAIDS. In AVAC Report. New York, NY: AVAC; 2009:54–63.
21.
•• Peterson L, Taylor D, Roddy R, et al.: Tenofovir disoproxil fumarate for prevention of HIV infection in women: A phase 2, doubleblind, randomized, placebo-controlled trial. PLoS Clin Trials 2007, 2:e27. This article evaluates efficacy and safety of oral tenofovir PrEP among 936 HIV-negative women.CrossRefPubMed
22.
•• Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al.: Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010, July 19: doi:10.​1126/​science.​1193748. This article evaluates effectiveness of a topical PrEP formulation among 889 HIV-negative women.
23.
Martin M, Vanichseni S, Suntharasamai P, et al.: Screening, enrollment, and follow-up of injecting drug users in an HIV pre-exposure prophylaxis trial in Bangkok [abstract WEPEC081]. Presented at the 5th IAS Conference on HIV Pathogenesis and Treatment. Cape Town, South Africa; 2009.
24.
Grohskopf L, Gvetadze R, Pathak S, et al: Preliminary analysis of biomedical data from the phase II clinical safety trial of tenofovir disoproxil fumarate (TDF) for HIV-1 pre-exposure prophylaxis (PrEP) among U.S. men who have sex with men (MSM) [abstract FRLBC102]. Presented at the XVIII International AIDS Conference. Vienna, Austria; 2010.
25.
Smith D, Kebaabetswe P, Disasi K, et al.: Antiretroviral resistance is not an important risk of the oral tenofovir prophylaxis trial in Botswana: a simple mathematical modelling approach [abstract THAX0105]. Presented at the XVI International AIDS Conference. Toronto, Canada; 2006.
26.
• Guest G, Shattuck D, Johnson L, et al.: Acceptability of PrEP for HIV prevention among women at high risk for HIV. J Womens Health 2010, In press. This article presents data on PrEP acceptability and adherence among a subset of women enrolled in a phase 2 PrEP trial.
27.
Lawoyin T, Alleman P, Guest G, MacQueen K: Factors influencing adherence to pills for pre-exposure prophylaxis: lessons learned from a phase 2 trial [abstract TUPE0423]. Presented at the XVI International AIDS Conference. Toronto, Canada; 2006.
28.
Lama JR, Guanira JV, Casapia M, et al.: iPrEx: successful initiation of a HIV pre exposure prophylaxis trial in high risk men [abstract WEPE0256]. Presented at the XVII International AIDS Conference. Mexico City, Mexico; 2008.
29.
• Guest G, Shattuck D, Johnson L, et al.: Changes in sexual risk behavior among participants in a PrEP HIV prevention trial. Sex Transm Dis 2008, 35:1002–1008. This article presents qualitative and quantitatve data on sexual risk behavior among a subset of women enrolled in a phase 2 PrEP trial.PubMed
30.
Vanichseni S, Martin M, Suntharasamai P, et al.: HIV-associated risk behavior among injecting drug users participating in an HIV pre-exposure prophylaxis trial in Bangkok [abstract WEPDC103]. Presented at the 5th IAS Conference on HIV Pathogenesis and Treatment. Cape Town, South Africa; 2009.
31.
Sood N, Goldman D: HIV breakthroughs and risky sexual behavior. Q J Econ 2006, 121:1063–1102.CrossRef
32.
Grant RM: Antiretroviral agents used by HIV-uninfected persons for prevention: pre- and postexposure prophylaxis. Clin Infect Dis 2010, 50(Suppl 3):S96–S101.CrossRefPubMed
33.
Klosinski LE: HIV testing from a community perspective. J Acquir Immune Defic Syndr 2000, 25:S94–S96.CrossRefPubMed
34.
Pinkerton SD, Bogart LM, Howerton D, et al.: Cost of rapid testing at 45 U.S. hospitals. AIDS Patient Care STDs 2010, 24:409–413.CrossRefPubMed
35.
Bartlett JG, Branson BM, Fenton K, et al.: Opt-out testing for human immunodeficiency virus in the United States. JAMA 2008, 300:945–951.CrossRefPubMed
36.
Kates J, Levi J: Insurance coverage and access to HIV testing and treatment: Considerations for individuals at risk for infection and for those with undiagnosed infection. Clin Infect Dis 2007, 45:S255–S260.CrossRefPubMed
37.
McCollum ED, Preidis GA, Kabue MM, et al.: Task shifting routine inpatient pediatric HIV testing improves program outcomes in urban Malawi: a retrospective observational study. PLoS One 2010, 5:e9626.CrossRefPubMed
38.
Bateganya M, Abdulwadud OA, Kiene SM: Home-based HIV voluntary counselling and testing (VCT) for improving uptake of HIV testing. Cochrane Database Syst Rev 2010, 7:CD006493.
39.
Gaguli I, Bassett IV, Dong KL, Walensky RP: Home testing for HIV infection in resource-limited settings. Curr HIV/AIDS Rep 2009, 6:217–223.CrossRef
40.
Monjok E, Smesny A, Mgbere O, Essien EJ: Routine HIV testing in health care settings: The deterrent factors to maximal implementation in Sub-Saharan Africa. J Int Assoc Physicians AIDS Care 2010, 9:23–29.CrossRef
41.
AIDS Vaccine Advocacy Coalition: Anticipating the results of PrEP trials: a powerful new HIV prevention tool may be on the horizon. Are we prepared? New York, NY: AVAC; 2008.
42.
Smith DK, Sutton M: What we don’t know and when should we know it: anticipating disparities in implementing biomedical prevention methods in the U.S. [abstract MOPE0448]. Presented at the XVII International AIDS Conference. Mexico City, Mexico; 2008.
43.
CDC: Pre-exposure prophylaxis (PrEP) for HIV prevention: Planning for potential implementation in the U.S. [Fact Sheet]. Atlanta, GA: CDC; 2009.
44.
Mack N, Mwale B, Lanham M, et al.: Anticipatory planning for PrEP rollout in Malawi based on country priorities [abstract WEPE0261]. Presented at the XVII International AIDS Conference. Mexico City, Mexico; 2008.
45.
46.
CDC: Summary report from the expert consultation on the implications of tenofovir as HIV chemoprophylaxis. Atlanta, GA: CDC; 2004.
47.
Vernazza P, Brenner I, Graf I: Pre-exposure prophylaxis and timed intercourse for HIV-discordant couples willing to conceive a child [abstract MOPDC01]. Presented at the 4th IAS Conference on HIV Pathogenesis, Treatment, and Prevention. Sydney, Australia; 2007.
48.
Cunningham W, Galea J, Kinsler J, et al.: The acceptability of pre-exposure prophylaxis (PrEP) for HIV prevention in Lima, Peru [abstract WEPE0260]. Presented at the XVII International AIDS Conference. Mexico City, Mexico; 2008.
49.
Lama JR, Guanira J, Goicochea P, et al.: Willingness to participate in a HIV pre-exposure prophylaxis efficacy trial among high risk men who have sex with men in the Andean region [abstract MOPEC038]. Presented at the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Sydney, Australia; 2005.
50.
Jommaroeng R, Chaitiamrus S, Apornpong T, et al.: Willingness to participate in HIV prevention trials is high among FSW, MSM, youth, and IDU in Bangkok, Thailand [abstract TUPDC05]. Presented at the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Sydney, Australia; 2007.
51.
Nodin N, Carballo-Dieguez A, Ventuneac AM, et al.: Knowledge and acceptability of alternative HIV prevention bio-medical products among MSM who bareback. AIDS Care 2008, 20:106–115.CrossRefPubMed
52.
Liu AY, Kittredge PV, Vittinghoff E, et al.: Limited knowledge and use of HIV post- and pre-exposure prophylaxis among gay and bisexual men. J Acquir Immune Defic Syndr 2008, 47:241–247.CrossRefPubMed
53.
Dunkle K, Wingood G, Camp C, DiClemente R: Intention to use pre-exposure prophylaxis among African-American and white women in the United States: results from a national telephone survey [abstract WEPE0258]. Presented at the XVII International AIDS Conference. Mexico City, Mexico; 2008.
54.
Mimiaga MJ, Case P, Johnson CV, et al.: Preexposure antiretroviral prophylaxis attitudes in high-risk Boston area men who report having sex with men: limited knowledge and experience but potential for increased utilization after education. J Acquir Immune Defic Syndr 2009, 50:77–83.CrossRefPubMed
55.
Schneider J, Oruganti G, Pasupneti S, et al.: Comparison of acceptability towards circumcision (Circ), pre-exposure prophylaxis (PREP) and herpes simplex suppression (HSV-S) as novel HIV prevention strategies amongst truck drivers in India [abstract WEPEC105]. Presented at the 5th IAS Conference on HIV Pathogenesis and Treatment. Cape Town, South Africa; 2009.
56.
Imrie J, Elford J, Kippax S, Hart GJ: Biomedical HIV prevention—and social science. Lancet 2007, 370:10–11.CrossRefPubMed
57.
AIDS Vaccine Advocacy Coalition: Summary from the AVAC think tank on PrEP financing in the US. San Francisco, CA: AVAC; 2009.
58.
Fisher K, Bass E, Feuer C, et al.: Who pays if PrEP works? Potential challenges to PrEP delivery in the United States [abstract CDC049]. Presented at the 5th IAS Conference on HIV Pathogenesis and Treatment. Cape Town, South Africa; 2009.
59.
Global HIV Prevention Working Group: Bringing HIV prevention to scale: An urgent global priority. Bill & Melinda Gates Foundation, Henry J. Kaiser Family Foundation; 2007.
60.
Novogrodsky N: The duty of treatment: Human rights and the HIV/AIDS pandemic. Yale Human Rights and Development Law Journal 2009, 12:1–61.
61.
Coates TJ, Richter L, Caceres C: Behavioural strategies to reduce HIV transmission: how to make them work better. Lancet 2008, 372:669–684.CrossRefPubMed
62.
Mills EJ, Singh S, Singh JA, et al.: Designing research in vulnerable populations: lessons from HIV prevention trials that stopped early. BMJ 2005, 331:1403–1406.CrossRefPubMed
63.
Kellerman SE, Hutchinson AB, Begley EB, et al.: Knowledge and use of HIV pre-exposure prophylaxis among attendees of minority gay pride events, 2004. J Acquir Immune Defic Syndr 2006, 43:376–377.CrossRefPubMed
64.
Voetsch AC, Heffelfinger JD, Begley EB, et al.: Knowledge and use of preexposure and postexposure prophylaxis among attendees of minority gay pride events, 2005 through 2006. J Acquir Immune Defic Syndr 2007, 46:378–380.CrossRefPubMed
65.
Peersman G, Rugg D, Erkkola T, et al.: Are the investments in national HIV monitoring and evaluation systems paying off? J Acquir Immune Defic Syndr 2009, 52:S87–S96.CrossRefPubMed
66.
Gallagher KM, Sullivan PS, Lansky A, Onorato IM: Behavioral surveillance among people at risk for HIV infection in the U.S.: The National HIV Behavioral Surveillance System. Public Health Rep 2007, 122:32–38.PubMed
67.
Beck EJ, Santas XM, DeLay PR: Why and how to monitor the cost and evaluate the cost-effectiveness of HIV services in countries. AIDS 2008, 22:S75–S85.CrossRefPubMed
Metadata
Title
Implementation Science of Pre-exposure Prophylaxis: Preparing for Public Use
Authors
Kristen Underhill
Don Operario
Matthew J. Mimiaga
Margie R. Skeer
Kenneth H. Mayer
Publication date
01-11-2010
Publisher
Current Science Inc.
Published in
Current HIV/AIDS Reports / Issue 4/2010
Print ISSN: 1548-3568
Electronic ISSN: 1548-3576
DOI
https://doi.org/10.1007/s11904-010-0062-4

Other articles of this Issue 4/2010

Current HIV/AIDS Reports 4/2010 Go to the issue

ReviewPaper

Readiness: The State of the Science (or the Lack Thereof)

ReviewPaper

Alcohol and HIV Disease Progression: Weighing the Evidence

ReviewPaper

The Four Cs of HIV Prevention with African Americans: Crisis, Condoms, Culture, and Community

ReviewPaper

Drug Treatment as HIV Prevention: Expanding Treatment Options

ReviewPaper

Increasing and Supporting the Participation of Persons of Color Living with HIV/AIDS in AIDS Clinical Trials

ReviewPaper

Pre-exposure Prophylaxis State of the Science: Empirical Analogies for Research and Implementation
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits